title: Raised HDL cholesterol in Fabry disease: response to enzyme replacement therapy.
abstract: Fabry disease patients have increased risk of vascular disease despite cardioprotective increased HDL-cholesterol. Enzyme therapy does not significantly alter the lipid profile in the short term.
authors.affiliation: Charles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery, London, UK.
authors.forename: D J
authors.initials: DJ
authors.lastname: Cartwright
authors.forename: A L
authors.initials: AL
authors.lastname: Cole
authors.forename: A J
authors.initials: AJ
authors.lastname: Cousins
authors.forename: P J
authors.initials: PJ
authors.lastname: Lee
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D008076:Cholesterol, HDL / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood; D000795:Fabry Disease / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood* / Q000209:etiology*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012727:Sex Characteristics; D000519:alpha-Galactosidase / Q000627:therapeutic use*
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008055:Lipids; D000519:alpha-Galactosidase